A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Esophageal Squamous Cell Carcinoma (ESCC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 90 (final count)
- Started
- Jul 27, 2022
- Main results expected
- Dec 5, 2025
- Fully finished
- Dec 5, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in Phase
Measured over: Up to approximately 3 weeks
Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in Phase
Measured over: Up to approximately 3 Weeks
Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in Phase
Measured over: Up to approximately 3 weeks
Objective Response Rate (ORR)
Measured over: Up to approximately 40 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05342636 · record last updated 2025-12-17 · checked 2026-11-09 15:47 UTC